Michaela A. Dinan, PhD, has been appointed Co-Leader of the Cancer Prevention and Control (CPC) Research Program at Yale Cancer Center (YCC) beginning January 1, 2021. Dinan was also named Associate Professor in the Department of Chronic Disease Epidemiology at the Yale School of Public Health and will also be a core faculty member of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale.
“Dr. Dinan will be an integral member of the YCC leadership team and will undoubtedly make a profound impact on the great research from our Cancer Prevention and Control Research Program and our Cancer Center,” said Charles Fuchs, MD, MPH, Director of YCC and Physician-in-Chief at Smilow Cancer Hospital. “We look forward to her leadership in this important area to help us improve the lives of our cancer patients.”
Dinan joins YCC from Duke Cancer Institute/Duke Clinical Research Institute where she was an Associate Professor in the Department of Population Health Sciences within the Department of Medicine, Medical Oncology, and where she also co-led the Patient Experience and Survivorship Focus Area in the Cancer Control and Population Sciences Program. She received her undergraduate degree from the University of Virginia in biology and her PhD from the University of North Carolina at Chapel Hill in health policy and management. Dinan’s research focuses on emerging medical technology in cancer using nationally representative, longitudinal data to examine trends in the evaluation and management of cancer, associated outcomes, and costs. Dinan is currently funded by the National Cancer Institute to study Disparities in the Use of Oral Anticancer Agents in Kidney Cancer.
“I look forward to working closely with Dr. Dinan,” said Melinda Irwin, PhD, Associate Director for Population Sciences at YCC. “She, along with CPC co-leader Xiaomei Ma, will help advance our mission to identify the causes of human cancers, assess patterns of care received by patients with cancer to then develop social, behavioral and therapeutic approaches to translate these findings into public health interventions to reduce cancer incidence, morbidity, and mortality.”